Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone.

Slides:



Advertisements
Similar presentations
A review on the luteal phase P Devroey MD PhD Centre for Reproductive Medicine Dutch-speaking Brussels Free University Brussels - Belgium.
Advertisements

Early-stage endometriosis: adhesion and growth of human menstrual endometrium in nude mice Michelle Nisolle, M.D., Ph.D., Françoise Casanas-Roux, B.S.,
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis  George Griesinger, M.D.,
J. C. Castillo, M. Dolz, E. Bienvenido, L. Abad, E. M. Casañ, F
J. C. Castillo, M. Dolz, E. Bienvenido, L. Abad, E. M. Casañ, F
Pseudocyesis The Journal for Nurse Practitioners
Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi.
Developmental capacity of in vitro–matured human oocytes retrieved from polycystic ovary syndrome ovaries containing no follicles larger than 6 mm  Luis.
Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis 
Treating endometriosis as an autoimmune disease
Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,
Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.
Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis  Ioannis P. Kosmas, M.D.,
No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH  George Griesinger, Daniel B. Shapiro, Efstratios.
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Anti-Müllerian hormone for the assessment of ovarian response in GnRH-antagonist- treated oocyte donors  Nikolaos P. Polyzos, Dominic Stoop, Christophe.
The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.
A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer 
Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.
Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D
The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility  Alexander M. Quaas, M.D.,
A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data 
Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis 
Microdose follicular phase gonadotropin-releasing hormone agonists (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization5 
Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D
Follicular and endocrine profiles associated with different GnRH-antagonist regimens: a randomized controlled trial  Juan Antonio García-Velasco, Sanja.
Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.
Michael J. Levy, William Ledger, Efstratios M. Kolibianakis, Pieta C
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.
Variations in l-selectin ligand expression in the luteal-phase endometrium after final oocyte maturation with human chorionic gonadotropin compared with.
A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin.
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Gene expression during successful implantation in a natural cycle
How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis  Dimitra Kyrou,
Effect of letrozole at 2. 5 mg or 5
Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis  Rina Agrawal,
Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study  Carlo.
Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.
Endometrial morphology and modulation of hormone receptors during ovarian stimulation for assisted reproductive technology cycles  Laura Detti, M.D.,
Perimenstrual asthma: A syndrome without known cause or cure
Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting  Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.
Concentrations of inhibins and activin in women undergoing stimulation with recombinant follicle-stimulating hormone for in vitro fertilization treatment 
Predictive usefulness of cycle day 10 follicle-stimulating hormone level in a clomiphene citrate challenge test for in vitro fertilization outcome in.
GnRH antagonists may affect endometrial receptivity
A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro.
Effectiveness of highly purified human menopausal gonadotropin vs
Sperm to zona pellucida binding depends on the use of a gonadotropin-releasing hormone agonist or a gonadotropin-releasing hormone antagonist  Annika.
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.
Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection.
Pharmacokinetics and pharmacodynamics of single-chain recombinant human follicle- stimulating hormone containing the human chorionic gonadotropin carboxyterminal.
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.
Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization  Efstratios M Kolibianakis, M.D., Kostas.
Economic evaluation of highly purified menotropin compared with recombinant follicle- stimulating hormone in assisted reproduction  Adam Lloyd, M.Phil.,
Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone–releasing hormone antagonist.
A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human.
Lower levels of inhibin A and pro-αC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human.
First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for.
Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists 
Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation 
Effectiveness of human menopausal gonadotropin versus recombinant follicle- stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive.
Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles 
Increased pregnancy rates after ultralong postoperative therapy with gonadotropin- releasing hormone analogs in patients with endometriosis  Dagmar Rickes,
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.
Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.
In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation 
Ernesto Bosch, M. D. , Elena Labarta, M. D
Presentation transcript:

Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone and gonadotropin- releasing hormone antagonists  Efstratios M Kolibianakis, MD, Claire Bourgain, MD, Peter Platteau, MD, Carola Albano, MD, Andre C Van Steirteghem, MD, PhD, Paul Devroey, MD, PhD  Fertility and Sterility  Volume 80, Issue 2, Pages 464-466 (August 2003) DOI: 10.1016/S0015-0282(03)00663-0

FIGURE 1 Difference between histologic and chronologic dating of endometrium at oocyte pick-up (open circles) and the mid-luteal phase (closed circles) after stimulation with recombinant FSH and GnRH antagonists and no luteal phase supplementation. Kolibianakis. GnRH antagonists and luteal phase endometrium.Fertil Steril 2003. Fertility and Sterility 2003 80, 464-466DOI: (10.1016/S0015-0282(03)00663-0)